PASG SEC Filings: 8-K, 10-Q, S-3 & 424B – Passage Bio

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Passage Bio Stockholders Approve Merger with Remix Therapeutics and Related Proposals

Nov 6, 2026

8-K

Passage Bio and Remix Therapeutics Amend Merger Agreement to Include Two-Step Structure and Pre-Funded Warrants

Sep 2, 2026

8-K

Passage Bio and Remix Therapeutics Announce Definitive Merger Agreement

Jun 24, 2026

8-K

Passage Bio Announces Termination of Gemma Collaboration and Office Lease Agreement

May 27, 2026

8-K

Passage Bio, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 26, 2026

8-K

Passage Bio Announces 75% Workforce Reduction as Part of Strategic Review

Apr 28, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

OFFERING - OTHER | Offering amount: $100,000,000 | Price: $3.730

Oct 9, 2026

425

Form 425 - Prospectuses and communications, business combinations

Sep 2, 2026

425

Form 425 - Prospectuses and communications, business combinations

Jul 21, 2026

425

Form 425 - Prospectuses and communications, business combinations

Jun 24, 2026

425

Form 425 - Prospectuses and communications, business combinations

Jun 24, 2026

424B5

ATM | Offering amount: $15,773,000 | Amount sold to date: $0 | Float: 62,061,774

Mar 5, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 8, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 5, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Sep 21, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Sep 2, 2026

S-4

Redwood Valuation Consents to Inclusion of Fairness Opinion in Passage Bio and Remix Therapeutics Merger Proxy EFFECTIVE, DATED 2026-10-09

Jul 21, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 4, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 7, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 16, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 16, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 4, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2024

Ownerships

TYPE

HEADLINE

FILED AT

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 8, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 5, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Sep 21, 2026

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Sep 2, 2026

SCHEDULE 13G/A

Vestal Point Capital, LP (Filed by)

Aug 14, 2026

S-4

Form S-4 - Registration of securities, business combinations

Jul 21, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 13, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 17, 2024

CORRESP

Form CORRESP - Correspondence

Apr 12, 2024

LETTER

Form UPLOAD - SEC-generated letter

Mar 7, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 15, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 22, 2021

Passage Bio, Inc. PASG · SEC Filings